Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 7 | 2024 | 204 | 4.110 |
Why?
|
| Radiation Tolerance | 6 | 2024 | 84 | 2.900 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2024 | 30 | 2.610 |
Why?
|
| MicroRNAs | 3 | 2024 | 345 | 1.160 |
Why?
|
| Inflammatory Breast Neoplasms | 3 | 2017 | 4 | 1.130 |
Why?
|
| Cell Line, Tumor | 12 | 2024 | 1392 | 1.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2024 | 80 | 1.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 210 | 1.060 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 97 | 1.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 997 | 1.000 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 18 | 0.980 |
Why?
|
| Tumor Burden | 3 | 2020 | 130 | 0.970 |
Why?
|
| Thyroid Neoplasms | 2 | 2024 | 109 | 0.930 |
Why?
|
| CDC2 Protein Kinase | 1 | 2024 | 17 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 831 | 0.880 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 67 | 0.870 |
Why?
|
| Signal Transduction | 4 | 2024 | 1608 | 0.830 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 410 | 0.730 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 119 | 0.660 |
Why?
|
| Neutrophils | 1 | 2021 | 142 | 0.660 |
Why?
|
| Mutation | 2 | 2024 | 1275 | 0.640 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 120 | 0.640 |
Why?
|
| Physicians | 1 | 2022 | 235 | 0.630 |
Why?
|
| Cell Movement | 2 | 2016 | 244 | 0.610 |
Why?
|
| Melanoma | 1 | 2021 | 278 | 0.590 |
Why?
|
| Forkhead Transcription Factors | 2 | 2015 | 110 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 138 | 0.570 |
Why?
|
| Macrophages | 2 | 2017 | 365 | 0.550 |
Why?
|
| Paracrine Communication | 1 | 2016 | 12 | 0.540 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1198 | 0.530 |
Why?
|
| Simvastatin | 1 | 2015 | 29 | 0.490 |
Why?
|
| Interleukin-6 | 1 | 2016 | 261 | 0.480 |
Why?
|
| Internship and Residency | 1 | 2020 | 443 | 0.480 |
Why?
|
| Lipoproteins, VLDL | 1 | 2015 | 9 | 0.480 |
Why?
|
| Humans | 23 | 2024 | 50417 | 0.460 |
Why?
|
| Mice, Nude | 4 | 2024 | 247 | 0.440 |
Why?
|
| Animals | 9 | 2024 | 13062 | 0.420 |
Why?
|
| Mice, SCID | 3 | 2020 | 171 | 0.420 |
Why?
|
| Mice | 7 | 2024 | 5658 | 0.420 |
Why?
|
| Inflammation | 1 | 2016 | 607 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 622 | 0.370 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1165 | 0.350 |
Why?
|
| Albumins | 2 | 2020 | 31 | 0.340 |
Why?
|
| Deoxycytidine | 2 | 2020 | 28 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 119 | 0.340 |
Why?
|
| Paclitaxel | 2 | 2020 | 84 | 0.340 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 416 | 0.320 |
Why?
|
| Female | 13 | 2022 | 27053 | 0.290 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 3233 | 0.260 |
Why?
|
| Thiazoles | 2 | 2024 | 54 | 0.250 |
Why?
|
| Cell Proliferation | 3 | 2020 | 980 | 0.240 |
Why?
|
| Retrospective Studies | 3 | 2022 | 6274 | 0.240 |
Why?
|
| Middle Aged | 6 | 2021 | 12579 | 0.240 |
Why?
|
| Quinolines | 1 | 2024 | 42 | 0.230 |
Why?
|
| Caveolae | 1 | 2024 | 6 | 0.220 |
Why?
|
| ras Proteins | 1 | 2024 | 65 | 0.220 |
Why?
|
| Endocytosis | 1 | 2024 | 62 | 0.210 |
Why?
|
| Transfection | 1 | 2024 | 353 | 0.210 |
Why?
|
| Hospitals, Community | 1 | 2022 | 19 | 0.200 |
Why?
|
| Career Mobility | 1 | 2022 | 28 | 0.200 |
Why?
|
| Arm | 1 | 2022 | 47 | 0.200 |
Why?
|
| DNA Damage | 1 | 2024 | 299 | 0.190 |
Why?
|
| Mentors | 1 | 2022 | 55 | 0.190 |
Why?
|
| Edema | 1 | 2022 | 69 | 0.190 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 738 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2022 | 91 | 0.190 |
Why?
|
| Cell Cycle | 2 | 2020 | 227 | 0.180 |
Why?
|
| Phosphorylation | 3 | 2017 | 520 | 0.170 |
Why?
|
| Caveolin 1 | 1 | 2020 | 21 | 0.170 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 221 | 0.170 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 89 | 0.170 |
Why?
|
| Faculty | 1 | 2020 | 71 | 0.170 |
Why?
|
| Leucovorin | 1 | 2020 | 20 | 0.170 |
Why?
|
| Male | 7 | 2021 | 25867 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 63 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2020 | 59 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2021 | 153 | 0.170 |
Why?
|
| Spleen | 1 | 2021 | 169 | 0.170 |
Why?
|
| Radiation Dosage | 1 | 2021 | 162 | 0.170 |
Why?
|
| Coculture Techniques | 2 | 2017 | 140 | 0.170 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 373 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 283 | 0.160 |
Why?
|
| Survival Rate | 3 | 2019 | 906 | 0.160 |
Why?
|
| Child | 2 | 2022 | 6931 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 153 | 0.160 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2019 | 51 | 0.150 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 65 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 462 | 0.150 |
Why?
|
| Aged | 3 | 2021 | 9738 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 221 | 0.150 |
Why?
|
| Adult | 4 | 2021 | 13561 | 0.140 |
Why?
|
| Interleukin-13 | 1 | 2017 | 14 | 0.140 |
Why?
|
| DNA Repair | 2 | 2019 | 187 | 0.140 |
Why?
|
| STAT6 Transcription Factor | 1 | 2017 | 7 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2017 | 16 | 0.140 |
Why?
|
| Interleukin-4 | 1 | 2017 | 42 | 0.140 |
Why?
|
| Mice, Knockout | 1 | 2020 | 840 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5265 | 0.140 |
Why?
|
| Protein Kinase C | 1 | 2017 | 71 | 0.140 |
Why?
|
| Cell Survival | 2 | 2019 | 587 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 155 | 0.140 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2016 | 10 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 396 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 77 | 0.130 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 9 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 288 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 269 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 56 | 0.120 |
Why?
|
| Prognosis | 1 | 2021 | 1974 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 90 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 17 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 597 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 27 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 230 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2015 | 36 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 102 | 0.120 |
Why?
|
| Cholesterol | 1 | 2015 | 150 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 376 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.100 |
Why?
|
| Receptor, Insulin | 1 | 2012 | 37 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 281 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2012 | 50 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 96 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 2933 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 386 | 0.080 |
Why?
|
| Apoptosis | 1 | 2012 | 1092 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 204 | 0.060 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 122 | 0.040 |
Why?
|
| Carboplatin | 1 | 2019 | 54 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 42 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2019 | 101 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2021 | 231 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 1029 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 117 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 125 | 0.040 |
Why?
|
| Chemokine CCL22 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Phosphopeptides | 1 | 2017 | 6 | 0.040 |
Why?
|
| src Homology Domains | 1 | 2017 | 9 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 10 | 0.040 |
Why?
|
| Biomimetic Materials | 1 | 2017 | 10 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2017 | 78 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 30 | 0.040 |
Why?
|
| Fibronectins | 1 | 2017 | 38 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 283 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2017 | 38 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 165 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2017 | 104 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 208 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 117 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 567 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2016 | 2 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 5 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 104 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 73 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 61 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 439 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 736 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 3648 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 924 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 59 | 0.030 |
Why?
|
| Triazines | 1 | 2012 | 24 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 227 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 453 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2012 | 111 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 387 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 575 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2012 | 187 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1431 | 0.020 |
Why?
|